Neurology

Andrew McKeon, M.B., B.Ch., M.D., an expert in neuroimmunology, joins the "Answers From the Lab" podcast for a conversation with Bobbi Pritt, M.D. In this episode, Dr. McKeon and Dr. Pritt discuss how Mayo Clinic is pioneering advancements in the field of autoimmune neurology, how these discoveries were made, and why they are important to both patients and physicians.

By Samantha Rossi • April 28, 2022

This “Specialty Testing” webinar will discuss the considerations physicians must weigh when evaluating suspected neuropathy patients with special emphasis put on small-fiber neuropathy and the most appropriate laboratory testing related to that phenotype.

By MCL Education • April 13, 2022

Mayo Clinic researchers have identified clear differences in brain and spinal cord scarring in patients with demyelinating diseases.

By Barbara J. Toman • April 8, 2022

Sophisticated laboratory testing solved a medical riddle and finally got Jori Pearson back on his feet, doing what he loves.

By Barbara J. Toman • April 4, 2022

Maria Alice Willrich, Ph.D., explains kappa free light chain testing — Mayo Clinic Laboratories' data-driven approach to diagnose multiple sclerosis. The automated assay is more sensitive, cost-effective, and faster than traditional oligoclonal banding, enabling definitive answers for the challenging diagnosis.

By Barbara J. Toman • March 29, 2022

Mayo Clinic researchers have developed and validated a new antibody test to diagnose multiple sclerosis (MS). The new test is an automated and cost-effective method compared to other tests used to diagnose MS, according to the research published in Mayo Clinic Proceedings. The test is now available through Mayo Clinic Laboratories.

By Suzanne Ferguson • March 24, 2022

Andrew McKeon, M.B., B.Ch., M.D., explains how Mayo Clinic Laboratories' stiff-person assay provides comprehensive evaluation for individuals on the spectrum of stiff-person syndrome. In addition to guiding treatment decisions, the assay can help confirm the most-severe stiff-person phenotype — known as PERM — which is associated with potential cancers.

By Barbara J. Toman • February 22, 2022

Lying in an ICU bed as sick as he could get, Jon Bratsch thought he was past the point of no return. But when a Mayo Clinic Laboratories’ test revealed the source of his dire symptoms, everything changed. Today, Jon’s back to the life and family he loves.

By Robin Huiras-Carlson • February 7, 2022

A tenacious fighter, Joy Carol never lost hope that a mysterious condition that had stripped her of her ability to move would be identified. Hope turned into reality when a Mayo Clinic Laboratories test identified the cause of her illness and opened the door to successful treatment.

By Robin Huiras-Carlson • January 24, 2022

Mayo Clinic Laboratories’ comprehensive approach to targeted antibody testing played a crucial and lifesaving role in moving Sheila Lewis to recovery from autoimmune encephalitis.

By Mayo Clinic Laboratories • January 3, 2022

Div Dubey, M.B.B.S., explains Mayo Clinic Laboratories' phenotypic testing approach for autoimmune axonal neuropathy. The comprehensive, serologic panel detects for antibodies with clinical relevance to the disease to provide clarity on etiology, prognosis, and treatment choices.

By Samantha Rossi • December 28, 2021

The quest to create a test pinpointing the source of the rare, testicular cancer-associated illness successfully concluded in the summer of 2021.

By Robin Huiras-Carlson • December 8, 2021

While Gregor Heinrich never could have imagined that testicular cancer was related to his problems with his vision and gait, learning he was positive for KLHL11 protein biomarkers meant he could receive treatment for both the cancer and the illness behind it.

By Robin Huiras-Carlson • December 6, 2021